-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Bluejay Diagnostics (NASDAQ:BJDX) Trading 15.7% Higher
Bluejay Diagnostics (NASDAQ:BJDX) Trading 15.7% Higher
Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Rating) shares traded up 15.7% on Thursday . The stock traded as high as $0.48 and last traded at $0.45. 9,936 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 507,309 shares. The stock had previously closed at $0.39.
Bluejay Diagnostics Price Performance
The stock has a market capitalization of $9.07 million and a PE ratio of -1.02. The business's fifty day moving average price is $0.68 and its 200-day moving average price is $0.92.
Get Bluejay Diagnostics alerts:Bluejay Diagnostics (NASDAQ:BJDX – Get Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). On average, analysts expect that Bluejay Diagnostics, Inc. will post -0.29 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC purchased a new stake in shares of Bluejay Diagnostics during the second quarter valued at approximately $54,000. Virtu Financial LLC purchased a new position in Bluejay Diagnostics during the second quarter valued at $45,000. Finally, Millennium Management LLC purchased a new position in Bluejay Diagnostics during the second quarter valued at $27,000. 0.94% of the stock is currently owned by institutional investors.Bluejay Diagnostics Company Profile
(Get Rating)
Bluejay Diagnostics, Inc, a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components.
Recommended Stories
- Get a free copy of the StockNews.com research report on Bluejay Diagnostics (BJDX)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Rating) shares traded up 15.7% on Thursday . The stock traded as high as $0.48 and last traded at $0.45. 9,936 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 507,309 shares. The stock had previously closed at $0.39.
BlueJay診斷公司(納斯達克代碼：BJDX-GET Rating)股價週四上漲15.7%。該股一度漲至0.48美元，最後報0.45美元。午盤有9,936股易手，較507,309股的平均成交量下降98%。該股此前收盤價為0.39美元。
Bluejay Diagnostics Price Performance
BlueJay診斷公司性價比
The stock has a market capitalization of $9.07 million and a PE ratio of -1.02. The business's fifty day moving average price is $0.68 and its 200-day moving average price is $0.92.
該股市值為907萬美元，本益比為-1.02。該業務的50日移動均線價格為0.68美元，200日移動均線價格為0.92美元。
Bluejay Diagnostics (NASDAQ:BJDX – Get Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). On average, analysts expect that Bluejay Diagnostics, Inc. will post -0.29 earnings per share for the current fiscal year.
BlueJay Diagnostics(納斯達克代碼：BJDX-GET Rating)上一次公佈季度收益數據是在11月9日星期三。該公司公佈了本季度每股收益(0.14美元)，低於普遍預期的(0.08美元)和(0.06美元)。分析師平均預計Bluejay Diagnostics，Inc.本財年每股收益將為0.29美元。
Institutional Inflows and Outflows
機構資金流入和流出
Bluejay Diagnostics Company Profile
BlueJay診斷公司簡介
(Get Rating)
(獲取評級)
Bluejay Diagnostics, Inc, a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components.
BlueJay診斷公司是一家診斷公司，在美國開發和銷售用於分診、診斷和監測疾病進展的患者產品。它正在開發一個技術平臺，包括使用非接觸式離心力協調血液處理、生物標記物分離和免疫分析準備的SYMPHONY螢光免疫分析儀；以及包括試劑和元件的SYMPHONY卡片庫。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Bluejay Diagnostics (BJDX)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- 免費獲取StockNews.com關於Bluejay診斷的研究報告(BJDX)
- 你買下Palantir的決定可能只是個時間問題
- 卡特彼勒和迪爾準備在2023年重整旗鼓嗎？
- 馬倫汽車公司在i-Go登陸歐洲之際受到震動
- 2023年，太陽會照耀這3只大盤太陽能股嗎？
- Lucid Motors面臨的現實可能會給看漲的看法蒙上陰影
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
接收Bluejay診斷日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收Bluejay Diagnostics和相關公司的最新新聞和分析師評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧